OCProDx

A multi-protein biomarker blood test for organ confined prostate cancer

OCProDx has the ability to meet important end-user needs – both for the patient and the physician. Using a patient’s blood sample the test uses Multiple Reaction Monitoring (MRM) to measure the levels of a set of proteins in the blood which indicate if a prostate tumour has extended beyond the prostate or remains confined. Our expert team analyses this information to provide a confinement score. This is of huge benefit to men diagnosed with prostate cancer as it provides information to guide significant life changing decisions they will have to make about their treatment, all without the need for invasive surgery. Atturos plan to make the OCProDx test available by late 2021.

Prostate Cancer

What you need to know

The prostate gland is located in front of the rectum and below the bladder. It’s function is to produce a secretion which aids survival and motility of sperm. Prostate cancer is one of the most common cancers affecting men, and is the fifth leading cause of death from cancer in men1. Factors that increase the risk of prostate cancer include age, family history, and race, as well as various genetic and lifestyle factors2. Most prostate tumours are slow growing and not present any symptoms, however some do grow relatively quickly and require treatment. Many tumours do not present symptoms, though a common screening test called PSA (Prostate Specific Antigen) may indicate issues in the prostate.

The video below (courtesy of Oncolex3) provides useful diagrams and explanations of prostate cancer development. If you are concerned about prostate cancer talk to your doctor or visit our Information for Patients page.

SOURCES OF INFORMATION
  1. World Health Organisation – IARC

  2. Cancer.org

  3. Video courtesy of onclolex.org

 
Man Doing Blood Test
Doctor's Desk
 

The Problem

Prostate Cancer – knowing what to do is complicated

Over 1 in 7 men will be diagnosed with prostate cancer at some point in their lifetime. Despite this only 1 in 15 of these men will die from prostate cancer, and 98.9% of patients will survive over 5 years [1]. Most men with prostate cancer die with rather than of the disease. The graphic on the left [2] shows the impact that prostate cancer screening has on diagnosis.

These disparities can be attributed to a number of factors, including race, PSA screening, lifestyle habits, and access to healthcare. PSA screening has caused an increase in prostate cancer diagnosis, due to the low specificity of PSA as a prostate cancer marker [3]. This has led to many men being over diagnosed and overtreated. Being able to distinguish indolent prostate cancer from aggressive more serious disease is the key issue facing clinicians today.

Active surveillance has shown to be an effective management technique for low-risk prostate cancer, with up to 100% cancer-free survival after 10 years [4]. Earlier diagnosis of aggressive prostate cancer will also help patients receive the most appropriate course of treatment for them. OCProDx is the only test that measures biological features of the actual prostate tumour. By measuring and tracking the tumours potential to extend outside of the prostate, disease progression can be tracked independent of the need for biopsy.

SOURCES OF INFORMATION
  1. National Cancer Institute – SEER Program

  2. U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 2012.

  3. “The Problem With Prostate Screening”, Richard J. Ablin, New York Times, Nov 25 2014

  4. Preston, Mark A., et al. “Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.” Urologic Oncology: Seminars and Original Investigations. Vol. 33. No. 9. Elsevier, 2015.

Experiment

Information for Patients

Atturos’ aim is to help prostate cancer patients to make informed decisions about their health.

One in seven men will be diagnosed with prostate cancer in their lifetime. The majority of these cases are not life threatening, and with early detection can be treated effectively. There are a number of steps that need to be taken to determine the most appropriate treatment course for each patient. Not all prostate cancers are the same, and there are a number of factors that can influence the effectiveness of interventions. Before deciding on a course of treatment we encourage patients to talk to their doctor about any potential side effects and ask how the treatment will improve their health and quality of life.

Knowledge starts with information. We have provided a number of resources and support networks below to help patients get the right information and make informed decisions about their treatment choice.

SOURCES OF INFORMATION
 

©2020 Atturos Ltd.